Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
1.210
-0.030 (-2.42%)
At close: Nov 22, 2024, 4:00 PM
1.200
-0.010 (-0.83%)
After-hours: Nov 22, 2024, 6:23 PM EST
Century Therapeutics Revenue
Century Therapeutics had revenue of $791.00K in the quarter ending September 30, 2024, with 434.46% growth. This brings the company's revenue in the last twelve months to $2.68M, up 7.88% year-over-year. In the year 2023, Century Therapeutics had annual revenue of $2.24M, down -57.01%.
Revenue (ttm)
$2.68M
Revenue Growth
+7.88%
P/S Ratio
32.59
Revenue / Employee
$16,267
Employees
165
Market Cap
102.89M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.24M | -2.96M | -57.01% |
Dec 31, 2022 | 5.20M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Quipt Home Medical | 244.23M |
FONAR | 102.01M |
Akoya Biosciences | 86.82M |
Journey Medical | 57.77M |
Avalo Therapeutics | 820.00K |
Adagene | 815.75K |
Inovio Pharmaceuticals | 203.41K |
INmune Bio | 42.00K |
IPSC News
- 17 days ago - Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 18 days ago - Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference - GlobeNewsWire
- 2 months ago - Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer - GlobeNewsWire
- 3 months ago - Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101 - Seeking Alpha
- 6 months ago - Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting - GlobeNewsWire
- 7 months ago - Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - GlobeNewsWire